Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHF 5993 versus CHF 1535 in COPD
2020-002389-16Phase 3Active
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of beclomethasone dipropionate, formoterol and glycopyrronium in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Change from baseline in pre-dose morning FEV1 at week 28. Started Oct 2020; status: active.
02
Drugs
beclomethasone dipropionateformoterolglycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2020-002389-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002389-16.